View Older Stories View More Recent Stories
-
Raymond James comments on Doximity, Inc. (DOCS) post webinar: 'The expert hasn’t seen any changes to budgets for DTC spending'
-
Truist Securities Upgrades Doximity Inc (DOCS) to Buy
-
Evercore ISI on Doximity Inc (DOCS): 'we expect Doximity to remain the anchor professional and commercial platform'
-
This software stock has a 'Strong Buy' rating at Raymond James
-
Doximity settles securities lawsuit for $31 million
-
Raymond James on Doximity Inc (DOCS): 'We would continue to buy shares on the recent pullback'
-
Piper are buyers of 'these high quality, profitable, growth' stocks
-
Piper Sandler: 'We Would be Buyers of DOCS and PHR Following Pharma Marketing KOL Lunch'
-
BofA Securities on Doximity Inc (DOCS): 'No shift from DTC, but HCP growth is accelerating'
-
Piper: 'We Would be Buyers of DOCS and PHR Following Pharma Marketing KOL Lunch in Boston'
-
Morgan Stanley Upgrades Doximity Inc (DOCS) to Overweight
-
These are the best U.S. healthcare tech and distribution stocks to buy: Barclays
-
Wells Fargo Reiterates Equal Weight Rating on Doximity Inc (DOCS)
-
Raymond James Upgrades Doximity Inc (DOCS) to Strong Buy
-
Doximity, Inc. (DOCS) Tops Q2 EPS by 7c, Offers Guidance
-
BofA Securities Upgrades Doximity Inc (DOCS) to Buy
-
JPMorgan Downgrades Doximity Inc (DOCS) to Underweight
-
BofA Securities Reiterates Neutral Rating on Doximity Inc (DOCS)
-
Raymond James Reiterates Outperform Rating on Doximity Inc (DOCS)
-
BofA on Neutral Rated Doximity Inc (DOCS): 'We come away slightly more positive on DOCS'
-
Goldman Sachs Downgrades Doximity Inc (DOCS) to Sell
-
Doximity Inc (DOCS) PT Raised to $67 at Canaccord Genuity
-
Raymond James on Doximity Inc (DOCS): 'We still believe that Doximity’s reach of 80%+ of physicians on the platform represents a formidable moat'
-
Doximity Inc (DOCS) PT Raised to $75 at BofA Securities
-
Doximity, Inc. (DOCS) Announces Resignation of Chief Compliance Officer
-
Doximity Inc (DOCS) PT Raised to $69 at Piper Sandler
-
Doximity Inc (DOCS) PT Raised to $62 at Morgan Stanley
-
Doximity Inc (DOCS) PT Raised to $79 at Leerink Partners
-
Doximity Inc (DOCS) PT Raised to $75 at Raymond James
-
Doximity Inc (DOCS) PT Raised to $75 at Evercore ISI
-
Doximity, Inc. (DOCS) Tops Q1 EPS by 6c; offers guidance
-
Leerink Partners Reiterates Outperform Rating on Doximity Inc (DOCS)
-
Doximity Inc (DOCS) PT Raised to $62 at Wells Fargo
-
Wells Fargo Reiterates Equal Weight Rating on Doximity Inc (DOCS)
-
Evercore ISI Upgrades Doximity Inc (DOCS) to Outperform
-
Doximity Inc (DOCS) PT Raised to $62 at BofA Securities
-
Doximity, Inc. (DOCS) Jumps Following Bloomberg Report Trump Administration Said To Consider Crackdown On Pharma Ads
-
Doximity, Inc. (DOCS) Announces Resignation of Chief Strategy Officer
-
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm
-
Wells Fargo Reiterates Equal Weight Rating on Doximity Inc (DOCS)
-
BTIG Upgrades Doximity Inc (DOCS) to Buy
-
Raymond James Comments on Application Software Names VEEV and DOCS
-
Doximity Inc (DOCS) PT Lowered to $50 at Goldman Sachs
-
Doximity Shareholder Alert: Long-Term DOCS Investors Encouraged to Contact Kehoe Law Firm, P.C. - Breach of Fiduciary Duties Investigation
-
Doximity Inc (DOCS) PT Lowered to $52 at Truist as 'FY26 Outlook Disappoints'
-
Doximity Inc (DOCS) PT Lowered to $65 at Raymond James
-
Doximity Inc (DOCS) PT Lowered to $50 at Evercore ISI, Removed from TAP Outperform List
-
After-hours movers: Applied Materials, Take-Two, CAVA Group, Doximity
-
Doximity, Inc. (DOCS) Tops Q4 EPS by 11c; offers guidance
-
Leerink expects strong Q4 from Doximity, cuts target on valuation reset
